{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:21:49Z","timestamp":1780453309421,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20lm0203091h0002"],"award-info":[{"award-number":["20lm0203091h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s12094-021-02717-3","type":"journal-article","created":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T05:02:26Z","timestamp":1634965346000},"page":"568-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab"],"prefix":"10.1007","volume":"24","author":[{"given":"H.","family":"Ueki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hinata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Terakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3925-8730","authenticated-orcid":false,"given":"T.","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,23]]},"reference":[{"issue":"8","key":"2717_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11864-019-0665-y","volume":"20","author":"P Grivas","year":"2019","unstructured":"Grivas P, Yu EY. Role of targeted therapies in management of metastatic urothelial cancer in the era of immunotherapy. Curr Treat Options Oncol. 2019;20(8):67.","journal-title":"Curr Treat Options Oncol"},{"issue":"11","key":"2717_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"11","key":"2717_CR3","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MW Teng","year":"2015","unstructured":"Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139\u201345.","journal-title":"Cancer Res"},{"issue":"19","key":"2717_CR4","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064\u201374.","journal-title":"Clin Cancer Res"},{"key":"2717_CR5","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3389\/fonc.2019.01533","volume":"9","author":"J Cao","year":"2019","unstructured":"Cao J, Yang X, Li J, Wu H, Li P, Yao Z, et al. Screening and identifying immune-related cells and genes in the tumor microenvironment of bladder urothelial carcinoma: based on TCGA database and bioinformatics. Front Oncol. 2019;9:1533.","journal-title":"Front Oncol"},{"issue":"4","key":"2717_CR6","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/annonc\/mdv009","volume":"26","author":"J Bellmunt","year":"2015","unstructured":"Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015;26(4):812\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"2717_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/BLC-160067","volume":"2","author":"F Erlmeier","year":"2016","unstructured":"Erlmeier F, Seitz AK, Hatzichristodoulou G, Stecher L, Retz M, Gschwend JE, et al. The role of PD-L1 expression and intratumoral lymphocytes in response to perioperative chemotherapy for urothelial carcinoma. Bladder Cancer. 2016;2(4):425\u201332.","journal-title":"Bladder Cancer"},{"issue":"1","key":"2717_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.urolonc.2016.10.004","volume":"35","author":"TC Zhou","year":"2017","unstructured":"Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X. A review of the PD-1\/PD-L1 checkpoint in bladder cancer: from mediator of immune escape to target for treatment. Urol Oncol. 2017;35(1):14\u201320.","journal-title":"Urol Oncol"},{"issue":"10","key":"2717_CR9","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1007\/s00345-019-03065-2","volume":"38","author":"AM Aydin","year":"2020","unstructured":"Aydin AM, Baydar DE, Hazir B, Babaoglu B, Bilen CY. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World J Urol. 2020;38(10):2537\u201345.","journal-title":"World J Urol"},{"issue":"6","key":"2717_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467\u201377.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2717_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/cas.13887","volume":"110","author":"B Wang","year":"2019","unstructured":"Wang B, Pan W, Yang M, Yang W, He W, Chen X, et al. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Sci. 2019;110(2):489\u201398.","journal-title":"Cancer Sci"},{"issue":"2","key":"2717_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00345-015-1615-3","volume":"34","author":"T Horn","year":"2016","unstructured":"Horn T, Laus J, Seitz AK, Maurer T, Schmid SC, Wolf P, et al. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol. 2016;34(2):181\u20137.","journal-title":"World J Urol"},{"issue":"6","key":"2717_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.urolonc.2014.02.007","volume":"32","author":"G Sjodahl","year":"2014","unstructured":"Sjodahl G, Lovgren K, Lauss M, Chebil G, Patschan O, Gudjonsson S, et al. Infiltration of CD3(+) and CD68(+) cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors. Urol Oncol-Semin Ori. 2014;32(6):791\u20137.","journal-title":"Urol Oncol-Semin Ori"},{"issue":"2","key":"2717_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1349-7006.1999.tb00733.x","volume":"90","author":"Y Oji","year":"1999","unstructured":"Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, et al. Expression of the Wilms\u2019 tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res. 1999;90(2):194\u2013204.","journal-title":"Jpn J Cancer Res"},{"issue":"6","key":"2717_CR15","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/modpathol.3800588","volume":"19","author":"S Nakatsuka","year":"2006","unstructured":"Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006;19(6):804\u201314.","journal-title":"Mod Pathol"},{"issue":"5","key":"2717_CR16","doi-asserted-by":"publisher","first-page":"8924","DOI":"10.1038\/srep08924","volume":"9","author":"XW Qi","year":"2015","unstructured":"Qi XW, Zhang F, Wu H, Liu JL, Zong BG, Xu C, et al. Wilms\u2019 tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep. 2015;9(5):8924.","journal-title":"Sci Rep"},{"issue":"10","key":"2717_CR17","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76(10):3003\u201313.","journal-title":"Cancer Res"},{"issue":"29","key":"2717_CR18","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592\u2013600.","journal-title":"J Clin Oncol"},{"issue":"15","key":"2717_CR19","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.3390\/ijms21155390","volume":"21","author":"E Tomiyama","year":"2020","unstructured":"Tomiyama E, Fujita K, Rodriguez Pena MDC, Taheri D, Banno E, Kato T, et al. Expression of nectin-4 and PD-L1 in upper tract urothelial carcinoma. Int J Mol Sci. 2020;21(15):5390.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2717_CR20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3892\/ijo.2016.3786","volume":"50","author":"T Maki","year":"2017","unstructured":"Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, et al. Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification. Int J Oncol. 2017;50(1):129\u201340.","journal-title":"Int J Oncol"},{"issue":"10","key":"2717_CR21","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1111\/j.1464-410X.2010.10020.x","volume":"108","author":"ME Winerdal","year":"2011","unstructured":"Winerdal ME, Marits P, Winerdal M, Hasan M, Rosenblatt R, Tolf A, et al. FOXP3 and survival in urinary bladder cancer. BJU Int. 2011;108(10):1672\u20138.","journal-title":"BJU Int"},{"issue":"1","key":"2717_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejso.2013.08.023","volume":"40","author":"E Xylinas","year":"2014","unstructured":"Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Kufer R, et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2014;40(1):121\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"2717_CR23","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.3892\/or.2015.3933","volume":"33","author":"Y Huang","year":"2015","unstructured":"Huang Y, Zhang SD, McCrudden C, Chan KW, Lin Y, Kwok HF. The prognostic significance of PD-L1 in bladder cancer. Oncol Rep. 2015;33(6):3075\u201384.","journal-title":"Oncol Rep"},{"issue":"15","key":"2717_CR24","doi-asserted-by":"publisher","first-page":"12400","DOI":"10.18632\/oncotarget.24249","volume":"9","author":"J Liu","year":"2018","unstructured":"Liu J, Zhang C, Hu J, Tian Q, Wang X, Gu H, et al. Effectiveness of anti-PD-1\/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis. Oncotarget. 2018;9(15):12400\u20137.","journal-title":"Oncotarget"},{"issue":"1","key":"2717_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/BF02983241","volume":"78","author":"Y Oka","year":"2003","unstructured":"Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol. 2003;78(1):56\u201361.","journal-title":"Int J Hematol"},{"issue":"5","key":"2717_CR26","first-page":"1167","volume":"8","author":"Y Miyoshi","year":"2002","unstructured":"Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H, et al. High expression of Wilms\u2019 tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res. 2002;8(5):1167\u201371.","journal-title":"Clin Cancer Res"},{"issue":"10031","key":"2717_CR27","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. The Lancet. 2016;387(10031):1909\u201320.","journal-title":"The Lancet"},{"key":"2717_CR28","doi-asserted-by":"publisher","first-page":"101925","DOI":"10.1016\/j.ctrv.2019.101925","volume":"82","author":"T Powles","year":"2020","unstructured":"Powles T, Walker J, Andrew Williams J, Bellmunt J. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. Cancer Treat Rev. 2020;82:101925.","journal-title":"Cancer Treat Rev"},{"issue":"10236","key":"2717_CR29","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Arija J\u00c1A, Bamias A, Davis ID, De Santis M, Kikuchi E, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet. 2020;395(10236):1547\u201357.","journal-title":"The Lancet"},{"issue":"4","key":"2717_CR30","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","volume":"24","author":"DL Suzman","year":"2019","unstructured":"Suzman DL, Agrawal S, Ning YM, Maher VE, Fernandes LL, Karuri S, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncologist. 2019;24(4):563\u20139.","journal-title":"Oncologist"},{"issue":"10","key":"2717_CR31","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00262-016-1877-7","volume":"65","author":"M Lopez","year":"2016","unstructured":"Lopez M, Ghidouche A, Rochas C, Godelaine D, Carrasco J, Colau D, et al. Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4. Cancer Immunol Immunother. 2016;65(10):1177\u201388.","journal-title":"Cancer Immunol Immunother"},{"issue":"24","key":"2717_CR32","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.2217\/fon-2021-0273","volume":"17","author":"MD Galsky","year":"2021","unstructured":"Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, et al. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: phase III KEYNOTE-866 and KEYNOTE-905\/EV-303. Future Oncol. 2021;17(24):3137\u201350.","journal-title":"Future Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02717-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-021-02717-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02717-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T16:06:21Z","timestamp":1646064381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-021-02717-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,23]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2717"],"URL":"https:\/\/doi.org\/10.1007\/s12094-021-02717-3","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,23]]},"assertion":[{"value":"8 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. We consulted extensively with the IRB of Kobe University Hospital and approval was granted (No: B200209).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patient's consent has been obtained.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}